This study investigates the effectiveness of adding an investigational medication to standard treatment for cervical and vaginal cancer. The study focuses on patients with certain stages of cervical or vaginal cancer that cannot be treated with surgery alone. The purpose is to see if the investigational medication, combined with radiation and another drug, can improve the time patients live without the cancer getting worse, compared to the usual treatment of radiation and the other drug alone.

Participants will undergo different procedures depending on their assigned study arm. One arm will receive the investigational medication along with radiation therapy and a drug called cisplatin. The other arm will receive only radiation therapy and cisplatin. The investigational medication is being tested to see if it can increase the effectiveness of the standard treatment.

• Who can participate: Women aged 18 and older with stage IB2, II, IIIB, or IVA cervical cancer, or stage II-IVA vaginal cancer, who cannot have surgery alone may participate. Participants must not have uncontrolled diabetes, known brain metastases, or certain allergies, and must not be breastfeeding.
• Study details: Participants will be randomly assigned to receive either the investigational medication with radiation and cisplatin, or just radiation and cisplatin.